Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.2M fell 9.5% year over year, behind the -2.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Stock-based compensation amounted to 158.2% of revenue in FY2025, up 100.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -9.5% toward the trailing-twelve-month pace of -2.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.38M USD
- Year-over-year change
- +14.1%
- 4-year CAGR
- -3.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.38M | +14.1% |
| FY2024 | 2024-12-31 | 10.86M | -47.2% |
| FY2023 | 2023-12-31 | 20.54M | +36.6% |
| FY2022 | 2022-12-31 | 15.04M | +7.0% |
| FY2021 | 2021-12-31 | 14.06M | — |
Stock-Based Compensation vs competitors
How ACRS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.1% is the 5th highest of 8, against a peer median of +20.4%.
- Stock-based compensation amounts to 144.0% of revenue for ACRS, versus a peer median of 254.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.12M USD | +24.3% | +9.7% | 17.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M USD | -7.4% | +94.0% | 492.0% |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $32.3M USD | +20.4% | — | — |
| LTM Mar 2026 | $23.96M USD | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $12.05M USD | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $11.29M USD | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $2.88M USD | -66.7% | -9.8% | — | |
| LTM Mar 2026 | €2.48M EUR | -152.9% | — | 8455.2% | |
| FY2025 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ACRS) | — | +20.4% | +9.7% | 254.9% | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (90.87M) | (86.91M) | (88.48M) | (132.07M) | (64.92M) |
| Depreciation & Amortization | 923K | 797K | 863K | 807K | 454K |
| Deferred Income Tax | 752K | 0 | (367K) | 0 | 0 |
| Stock-Based Compensation | 14.06M | 15.04M | 20.54M | 10.86M | 12.38M |
| Change in Working Capital | (1.34M) | (1.2M) | 9.39M | 10.92M | 2.67M |
| Accounts Receivables | 149K | 139K | 186K | (20K) | 6.14M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.66M | 368K | (1.47M) | (4.19M) | 8.45M |
| Other Working Capital | (5.15M) | (1.7M) | 10.68M | 15.13M | (11.91M) |
| Other Non-Cash Items | 24.34M | 4.7M | (20.27M) | 89.41M | 2.3M |
| Operating Cash Flow | (52.13M) | (67.57M) | (78.33M) | (20.08M) | (47.11M) |
| Capital Expenditures | (308K) | (605K) | (1.31M) | (121K) | (111K) |
| Acquisitions (Net) | 167.32M | (13.23M) | 0 | 0 | 0 |
| Purchases of Investments | (235.15M) | (164.75M) | (135.68M) | (119.98M) | (39.73M) |
| Sales of Investments | 67.83M | 177.99M | 183.2M | 86.14M | 89.04M |
| Other Investing Activities | (167.32M) | 13.23M | 0 | (35.81M) | (833K) |
| Investing Cash Flow | (167.63M) | 12.63M | 46.22M | (69.77M) | 48.37M |
| Debt Repayment | (11.48M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 238.2M | 72.74M | 26.71M | 74.91M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.67M) | 123K | (8K) | (377K) | (5.86M) |
| Financing Cash Flow | 225.05M | 72.87M | 26.71M | 74.54M | (5.86M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.29M | 17.93M | (5.4M) | (15.31M) | (4.61M) |
| Free Cash Flow | (52.44M) | (68.17M) | (79.63M) | (20.2M) | (47.11M) |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.